Loading
LGR5 (Leucine-rich repeat-containing G protein-coupled receptor 5) is a protein on the cell surface. The public catalogues list it as a drug target, a biomarker and an antigen, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Sarcomas.
Receptor for R-spondins that potentiates the canonical Wnt signalling pathway and acts as a stem cell marker of the intestinal epithelium and the hair follicle. Upon binding to R-spondins (RSPO1, RSPO2, RSPO3 or RSPO4), associates with phosphorylated LRP6 and frizzled receptors that are activated by extracellular Wnt receptors, triggering the canonical Wnt signalling pathway to increase expression of target genes. In contrast to classical G protein-coupled receptors, does not activate heterotrimeric G proteins to transduce the signal.
CIViC holds 3 clinical evidence items and 0 assertions across 2 variants, naming Fluorouracil. In OnCo, 1 product record names it (Petosemtamab).
In plain words · LGR5 (Leucine-rich repeat-containing G protein-coupled receptor 5) is a protein on the cell surface. The public catalogues list it as a drug target, a biomarker and an antigen, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Sarcomas.
LGR5 (Leucine-rich repeat-containing G protein-coupled receptor 5) is a protein on the cell surface. The public catalogues list it as a drug target, a biomarker and an antigen, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Sarcomas.
Receptor for R-spondins that potentiates the canonical Wnt signalling pathway and acts as a stem cell marker of the intestinal epithelium and the hair follicle.
No product in this corpus aims at LGR5 yet. Because it sits on the outside of the cell, it can be reached from the bloodstream: antibodies flag the cell, ADCs deliver a toxin, radioligands deliver radiation, and CAR-T or bispecifics bring a T cell.
Tumour-associated overexpression: 1 antibody (Petosemtamab) aim at the antigen, which HPA finds stained high in 3 normal tissues; the medicine relies on the tumour carrying more of it than the normal tissue it shares it with. HPA LGR5: RNA tissue enhanced (fallopian tube 16 nTPM, placenta 18 nTPM, skeletal muscle 21 nTPM); high antibody staining in 3 normal tissues; highest cancer staining cervical cancer (2 of 11 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Colorectal cancer, Sarcomas (soft tissue, bone, GIST)); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 5 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas LGR5 tissue; Human Protein Atlas LGR5 pathology; Open Targets ENSG00000139292 associations
First described 1998. Earliest sequence paper UniProt cites for the protein: McDonald et al, Biochem. Biophys. Res. Commun, 1998, "Identification and cloning of an orphan G protein-coupled receptor of the glycoprotein hormone receptor subfamily". Source.
Sources: HGNC HGNC:4504 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O75473 (protein name, function text, keywords and locations (REST API)); CIViC gene LGR5 (3 evidence items, 0 assertions, 2 variants; diseases: Colorectal Cancer, Oral Squamous Cell Carcinoma, Sarcoma (GraphQL API, CC0))
Receptor for R-spondins that potentiates the canonical Wnt signalling pathway and acts as a stem cell marker of the intestinal epithelium and the hair follicle. Upon binding to R-spondins (RSPO1, RSPO2, RSPO3 or RSPO4), associates with phosphorylated LRP6 and frizzled receptors that are activated by extracellular Wnt receptors, triggering the canonical Wnt signalling pathway to increase expression of target genes. In contrast to classical G protein-coupled receptors, does not activate heterotrimeric G proteins to transduce the signal. Involved in the development and/or maintenance of the adult intestinal stem cells during postembryonic development. Location: Cell membrane; Golgi apparatus, trans-Golgi network membrane (UniProt). Locus 12q21.1 (HGNC).
RNA: tissue enhanced (fallopian tube 16 nTPM, placenta 18 nTPM, skeletal muscle 21 nTPM), detected in many normal tissues.
Medium: Cerebral cortex, Cervix, Duodenum, Placenta, Small intestine, Stomach.
RNA group enriched: Colon Adenocarcinoma 27 pTPM, Ovary Serous Cystadenocarcinoma 14 pTPM, Rectum Adenocarcinoma 29 pTPM, Stomach Adenocarcinoma 9 pTPM, Uterine Corpus Endometrial Carcinoma 36 pTPM.
Medium only: carcinoid, endometrial cancer, head and neck cancer, liver cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"LGR5" OR ABSTRACT:"LGR5" OR TITLE:"leucine rich repeat containing G protein-coupled receptor 5" OR ABSTRACT:"leucine rich repeat containing G protein-coupled receptor 5" OR TITLE:"Leucine-rich repeat-containing G protein-coupled receptor 5" OR ABSTRACT:"Leucine-rich repeat-containing G protein-coupled receptor 5" OR TITLE:"HG38" OR ABSTRACT:"HG38" OR TITLE:"GPR67" OR ABSTRACT:"GPR67" OR TITLE:"GPR49" OR ABSTRACT:"GPR49") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about LGR5, not a curated reading list.
Shares Petosemtamab, Wnt / β-catenin, Colorectal cancer.
Shares Petosemtamab, Colorectal cancer.
Shares Petosemtamab, Colorectal cancer.
Shares Wnt / β-catenin, Colorectal cancer.
Shares Petosemtamab, Colorectal cancer.
Shares Wnt / β-catenin, Colorectal cancer.
Shares Wnt / β-catenin, Colorectal cancer.
Shares Wnt / β-catenin, Colorectal cancer.